S. Stilgenbauer

Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12

U. Jaeger, C. Fonatsch, M. Bilban, 2009, European journal of clinical investigation.

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

S. Montoto, N. Kröger, A. Nagler, 2018, Bone Marrow Transplantation.

Non-canonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.

T. Aittokallio, D. Mougiakakos, M. Hallek, 2020, Blood.

B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.

J. Trapani, S. Lindner, C. Tam, 2014, International immunology.

Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group

M. Hallek, B. Schmidt, S. Kremers, 2016, Leukemia & lymphoma.

VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY

M. Hallek, K. Kreuzer, Yanwen Jiang, 2021, Hematological Oncology.

THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION

M. Hallek, P. Staber, K. Kreuzer, 2021, Hematological Oncology.

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

S. Montoto, N. Kröger, A. Nagler, 2018, Bone Marrow Transplantation.